Citations

Clear

861 citation(s) found for "Sd, Wexner".

Validating a Computable Phenotype for Nephrotic Syndrome in Children and Adults Using PCORnet Data
Marchel, Dorota , Tran, Cheryl L. , Greco, Jessica , Denburg, Michelle , Oliverio, Andrea L. , Ayoub, Isabelle , Almaani, Salem , Gipson, Debbie S , Mariani, Laura H.

Mayo Clinic

Journal of the American Society of Nephrology | May 17, 2024 | Volume: 31 | Issue: 10S | Pages: 582-582

10.1681/asn.20203110s1582b Get It

Comparative analysis of the tumor microbiome, molecular profiles, and immune cell abundances by HPV status in mucosal head and neck cancers and their impact on survival
Upadhyay, Rituraj , Dhakal, Aastha , Singh, Malvenderjit Jagjit, Karivedu, Vidhya , Bhateja, Priyanka, Valentin, Sasha, Gamez, Mauricio E. , Konieczkowski, David J. , Baliga, Sujith , Grecula, J.C., Blakaj, Dukagjin , Spakowicz, Daniel , Jhawar, Sachin R , Spakowicz, Daniel , Wheeler, Caroline E. , Hoyd, Rebecca , Bonomi, Marcelo , Gogineni, Emile , Mitchell, Darrion , Denko, Nicholas C. , Jhawar, Sachin R.

Mayo Clinic

Cancer Biology & Therapy | May 9, 2024 | Volume: 25 | Issue: 1 | Pages: No page available

10.1080/15384047.2024.2350249 | PMID 38722731 Get It

In Vitro Culture of Primary Human Lung Fibroblasts Induces Collagen Expression and Promotes the Expansion of CTHRC1-positive Cells
Vanegas, N.D.P., Ricardez, J.A. Ovando, Peters, V., Stacey, S.D., Gomperts, Bastien D., Tschumperlin, Daniel J. , Rodriguez-Lopez, Jhonny , Rodriguez-Lopez, Jhonny , Rodriguez-Lopez, J., Stacey, S.D., Mora, Ana Lucia , Rojas, Mauricio M.

Mayo Clinic

C28. MORE THAN MEET THE EYE: NOVEL INSIGHTS IN IPF PATHOGENESIS | April 30, 2024 | Volume: No volume available | Issue: No issue available | Pages: A5200-A5200

10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a5200 Get It

Efficacy and Safety of Avacopan Versus Prednisone Taper in Patients With ANCA-Associated Vasculitis With Lung Involvement: A Post Hoc Analysis of the ADVOCATE Trial
Fussner, Lynn A. , Bray, Sarah , Gurlin, Rachel E , Group, ADVOCATE Study, Specks, Ulrich , Jayne, David , Merkel, Peter A.

Mayo Clinic

A26. IMPROVING OUTCOMES IN SARCOIDOSIS, RARE LUNG DISEASE AND LUNG TRANSPLANT | April 30, 2024 | Volume: No volume available | Issue: No issue available | Pages: A1182-A1182

10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a1182 Get It

Abstract 12017: New-Onset Diabetes After Heart Transplantation is associated With Worse Long-term Survival: A Propensity Matched Analysis of a National Registry.
Sarabu, Nagaraju , Kumar, Sachin , Oliveira, Guilherme H., Deo, Salil V. , Altarabsheh, Salah E. , Dunlay, Shannon M. , Kılıç, Ahmet , Fonarow, Gregg C.

Mayo Clinic

Circulation | April 23, 2024 | Volume: 134 | Issue: suppl_1 | Pages: No page available

10.1161/circ.134.suppl_1.12017 Get It

Introduction: Limited data is available regarding the incidence of new-onset diabetes mellitus (NODM) after heart transplantation and it`s impact on patient survival. Hypothesis: Methods: From the United Network of Organ Sharing database (January 2004 to September 2014), we identified 13,353 patients without pre-operative diabetes mellitus undergoing heart transplantation. Multivariable Cox regression was implemented to determine predictors for the development of NODM. A matched cohort of New-onset Diabetes mellitus (NODM (+)) and NODM (-) was generated by 1:1 nearest neighbor propensity-matching. The association of NODM with long-term survival was then estimated with robust Cox regression. Results are presented at the 95% Confidence level; all tests are two-tailed. Results: During the study period, 1,921 of 13,353 (14%) developed NODM. Estimated freedom from NODM was 97% (96-98%) & 77% (76 - 78%) at the end of 1 and 5 years respectively. Predictors for the development of NODM were recipient age > 50 years (HR 1.2 95% CI1.05, 1.3; p < 0.01), recipient BMI > 30 (HR 1.4 95% CI1.2, 1.6; p < 0.01) and race (African American vs Caucasian (HR 1.3 95% CI1.2, 1.5; p < 0.01)). Cox-regression of a propensity-matched cohort of 1921 NODM+ve and NODM-ve recipient-pairs demonstrates that NODM is associated with poorer survival (HR for mortality: 1.3 95% CI 1.1, 1.5; p < 0.001). Conclusions: More than one in ten heart transplant recipients develop NODM post heart transplantation. Obesity, older age, and African American race patients to be at higher risk for NODM. New onset diabetes was independently associated with an almost 30% reduced long-term survival. More than one in ten heart transplant recipients develop NODM post heart transplantation. Obesity, older age, and African American race patients to be at higher risk for NODM. New onset diabetes was independently associated with an almost 30% reduced long-term survival.
The impact of multimorbidity and functional limitation on quality of life in patients with heart failure: A multi‐site study
Manemann, Sheila M., Haller, Irina V. , Horne, Benjamin D. , Lampert, Brent C. , Rasmusson, Kismet, Roger, Véronique L. , Weston, Susan A., Killian, Jill M. , Benziger, Catherine P , Hade, Erinn M. , Benziger, Catherine P. , Chamberlain, Alanna M.

Mayo Clinic

Journal of the American Geriatrics Society | April 18, 2024 | Volume: 72 | Issue: 6 | Pages: 1750-1759

10.1111/jgs.18924 | PMID 38634747 Get It

Abstract Background Multimorbidity and functional limitation are associated with poor outcomes in heart failure (HF). However, the individual and combined effect of these on health‐related quality of life in patients with HF is not well understood. Methods Patients aged ≥30 years with two or more HF diagnostic codes and one or more HF‐related prescription drugs from four U.S. institutions were mailed a survey to measure patient‐centric factors including functional status (activities of daily living [ADLs]) and health‐related quality of life (PROMIS‐29 Health Profile). Patients with HF from January 1, 2013 to February 1, 2018 were included. Multimorbidity was defined as ≥2 non‐cardiovascular comorbidities; functional limitation as any limitation in at least one of eight ADLs. Patients were categorized into four groups by multimorbidity (Yes/No) and functional limitation (Yes/No). We dichotomized the PROMIS‐29 sub‐scale scores at the median and calculated odd ratios for the four multimorbidity/functional limitation groups. Results A total of 3330 patients with HF returned the survey (response rate 31%); 3020 completed the questions of interest and were retained. Among these patients (45% female; mean age 73 [standard deviation: 12] years), 29% had neither multimorbidity nor functional limitation, 24% had multimorbidity only, 22% had functional limitation only, and 25% had both. After adjustment, having functional limitation only was associated with higher anxiety (odds ratio [OR]: 3.44, 95% confidence interval [CI]: 2.66–4.45), depression (OR: 3.11, 95% CI: 2.39–4.06), and fatigue (OR: 4.19, 95% CI: 3.25–5.40); worse sleep (OR: 2.14, 95% CI: 1.69–2.72) and pain (OR: 6.73, 95% CI: 5.15–8.78); and greater difficulty with social activities (OR: 9.40, 95% CI: 7.19–12.28) compared with having neither. Results were similar for having both multimorbidity and functional limitation. Conclusion Patients with only functional limitation have similar poor health‐related quality of life scores as those with both multimorbidity and functional limitation, underscoring the important role that physical functioning plays in the well‐being of patients with HF.
Incidence of staff injury and illness at the Tokyo 2020 and Beijing 2022 Olympic and Paralympic Games
Larson, Emily G., Hasley, Ike B., Post, Eric G. , Cali, Malia G. , Clark, Stephanie C., McPherson, April L. , Noble-Taylor, Kayle E, Anderson, Travis , Anderson, Travis , Adams, William M , Noble-Taylor, Kayle E., Robinson, David M. , Finnoff, Jonathan T. , Adams, William M.

Mayo Clinic

BMJ Open Sport & Exercise Medicine | April 17, 2024 | Volume: 10 | Issue: 2 | Pages: e001835

10.1136/bmjsem-2023-001835 | PMID 38645762 Get It

Objective To report epidemiological data regarding injury and illness among the Team USA staff during the Tokyo 2020 Summer Olympic and Paralympic Games and Beijing 2022 Winter Olympic and Paralympic Games. Methods A retrospective review of all Team USA staff (total staff, N=1703 (62.5% female); total staff days (SD)=34 489) medical encounters during the Tokyo 2020 Games and Beijing 2022 Games was conducted. Details related to injury and illness were evaluated. Incidence with 95% CI per 1000 staff days were calculated. Results A total of 32 illnesses (incidence [95% CI] 0.9 [0.6, 1.2]) and 23 injuries (incidence 0.7 [0.4, 0.9]) were sustained by the Team USA delegation staff members during the Tokyo 2020 Games and Beijing 2022 Games. Female staff reported more illnesses (illnesses proportion (IP) 2.9%; incidence 1.4 [0.8, 2.0]), while male staff incurred more injuries (IP 1.8%; incidence 0.9 [0.5, 1.3]). When stratified by physiological system, dermatological and infectious were the most common systems involved with illness (IP 0.5%; incidence 0.2 [0.1, 0.4]). Injuries to the upper limb were most common (IP 0.3%; incidence 0.3 [0.1, 0.5]). Conclusion Injury and illness rates among the Team USA staff during the Tokyo 2020 Games and Beijing 2022 Games were low, but notable. Knowledge of injury and illness risks contributes to staffing decisions and prevention strategies for staff supporting athletes during competition.
Atrial Shunt Device Effects on Cardiac Structure and Function in Heart Failure With Preserved Ejection Fraction
Silvestry, Frank E. , Komtebedde, Jan , Solomon, Scott D. , Price, Matthew J. , Kawash, Rami, Hummel, Scott L. , Cutlip, Donald E. , Leon, Martin B. , Veldhuisen, Dirk J. van , Rieth, Andreas , Bugger, Heiko , Mazurek, Jeremy A. , Ky, Bonnie , Ky, Bonnie , Hummel, Scott L , Patel, Ravi B. , Solomon, Scott David , Hasenfuß, Gerd , Litwin, Sheldon E. , Borlaug, Barry A. , McKenzie, Scott , Kapadia, Samir , Vanderheyden, Marc , Shah, Sanjiv J

Mayo Clinic

JAMA Cardiology | April 17, 2024 | Volume: 9 | Issue: 6 | Pages: 507

10.1001/jamacardio.2024.0520 | PMID 38630494 Get It

Importance Although the results of A Study to Evaluate the Corvia Medical Inc IASD System II to Reduce Elevated Left Atrial Pressure in Patients with Heart Failure (REDUCE LAP-HF II) trial were neutral overall, atrial shunt therapy demonstrated potential efficacy in responders (no latent pulmonary vascular disease and no cardiac rhythm management device). Post hoc analyses were conducted to evaluate the effect of shunt vs sham stratified by responder status. Objective To evaluate the effect of atrial shunt vs sham control on cardiac structure/function in the overall study and stratified by responder status. Design, Setting, and Participants This was a sham-controlled randomized clinical trial of an atrial shunt device in heart failure with preserved ejection fraction (HFpEF)/HF with mildly reduced EF (HFmrEF). Trial participants with evaluable echocardiography scans were recruited from 89 international medical centers. Data were analyzed from April 2023 to January 2024. Interventions Atrial shunt device or sham control. Main Outcome Measures Changes in echocardiographic measures from baseline to 1, 6, 12, and 24 months after index procedure. Results The modified intention-to-treat analysis of the REDUCE LAP-HF II trial included 621 randomized patients (median [IQR] age, 72.0 [66.0-77.0] years; 382 female [61.5%]; shunt arm, 309 [49.8%]; sham control arm, 312 [50.2%]). Through 24 months, 212 of 217 patients (98%) in the shunt arm with evaluable echocardiograms had patent shunts. In the overall trial population, the shunt reduced left ventricular (LV) end-diastolic volume (mean difference, −5.65 mL; P &amp;lt;.001), left atrial (LA) minimal volume (mean difference, −2.8 mL; P =.01), and improved LV systolic tissue Doppler velocity (mean difference, 0.69 cm/s; P &amp;lt;.001) and LA emptying fraction (mean difference, 1.88 percentage units; P =.02) compared with sham. Shunt treatment also increased right ventricular (RV; mean difference, 9.58 mL; P &amp;lt;.001) and right atrial (RA; mean difference, 9.71 mL; P &amp;lt;.001) volumes but had no effect on RV systolic function, pulmonary artery pressure, or RA pressure compared with sham. In the shunt arm, responders had smaller increases in RV end-diastolic volume (mean difference, 5.71 mL vs 15.18 mL; interaction P =.01), RV end-systolic volume (mean difference, 1.58 mL vs 7.89 mL; interaction P =.002), and RV/LV ratio (mean difference, 0.07 vs 0.20; interaction P &amp;lt;.001) and larger increases in transmitral A wave velocity (mean difference, 5.08 cm/s vs −1.97 cm/s; interaction P =.02) compared with nonresponders randomized to the shunt, suggesting greater ability to accommodate shunted blood through the pulmonary circulation enabling LA unloading. Conclusions and Relevance In this post hoc analysis of the REDUCE LAP-HF II trial, over 2 years of follow-up, atrial shunting led to reverse remodeling of left-sided chambers and increases in volume of right-sided chambers consistent with the shunt flow but no change in RV systolic function compared with sham. Changes in cardiac structure/function were more favorable in responders compared with nonresponders treated with the shunt, supporting the previously identified responder group hypothesis and mechanism, although further evaluation with longer follow-up is needed. Trial Registration ClinicalTrials.gov Identifier: NCT03088033
Clinical Decision Making in Inflammatory Bowel Disease Mimics: Practice Management from Inflammatory Bowel Disease LIVE
Fiske, Hannah W. , Shah, Samir A. , Al-Bawardy, Badr , Binion, David G. , Bohm, Matthew , Brand, Myron, Cohen, Benjamin L, Dueker, Jeffrey, Engels, Michael , Fine, Sean , Förster, E , Gaidos, Jill , Ginsburg, Philip, Goyal, Alka , Hanson, John S. , Herfath, Hans, Hull, Tracy L. , Kelly, Colleen , Lazarev, Mark , Levy, L. Campbell, Melia, Joanna , Philpott, Jessica, Qazi, Taha , Watson, Andrew , Wexner, Steven D. , Williams, Emmanuelle, Al‐Bawardy, Badr , Al-Bawardy, Badr , Bohm, Matthew , Fine, Sean , Forster, Erin , Gaidos, Jill K J , Hull, Tracy , Melia, Joanna , Qazi, Taha , Regueiro, Miguel , Wexner, Steven D , Ward, Chris , Holubar, Stefan D. , Barnes, Edward L. , Clarke, Kofi , Cohen, Benjamin L, Cross, Raymond K. , Farraye, Francis A. , Hanson, John, Philpott, Jessica R., Siegel, Corey A , Regueiro, Miguel

Mayo Clinic

Crohn's & Colitis 360 | April 10, 2024 | Volume: 6 | Issue: 2 | Pages: No page available

10.1093/crocol/otae022 | PMID 38720935 Get It

Abstract Background Since 2009, inflammatory bowel disease (IBD) specialists have utilized “IBD LIVE,” a weekly live video conference with a global audience, to discuss the multidisciplinary management of their most challenging cases. While most cases presented were confirmed IBD, a substantial number were diseases that mimic IBD. We have categorized all IBD LIVE cases and identified “IBD-mimics” with consequent clinical management implications. Methods Cases have been recorded/archived since May 2018; we reviewed all 371 cases from May 2018–February 2023. IBD-mimics were analyzed/categorized according to their diagnostic and therapeutic workup. Results Confirmed IBD cases made up 82.5% (306/371; 193 Crohn’s disease, 107 ulcerative colitis, and 6 IBD-unclassified). Sixty-five (17.5%) cases were found to be mimics, most commonly medication-induced (n = 8) or vasculitis (n = 7). The evaluations that ultimately resulted in correct diagnosis included additional endoscopic biopsies (n = 13, 21%), surgical exploration/pathology (n = 10, 16.5%), biopsies from outside the GI tract (n = 10, 16.5%), genetic/laboratory testing (n = 8, 13%), extensive review of patient history (n = 8, 13%), imaging (n = 5, 8%), balloon enteroscopy (n = 5, 8%), and capsule endoscopy (n = 2, 3%). Twenty-five patients (25/65, 38%) were treated with biologics for presumed IBD, 5 of whom subsequently experienced adverse events requiring discontinuation of the biologic. Many patients were prescribed steroids, azathioprine, mercaptopurine, or methotrexate, and 3 were trialed on tofacitinib. Conclusions The diverse presentation of IBD and IBD-mimics necessitates periodic consideration of the differential diagnosis, and reassessment of treatment in presumed IBD patients without appropriate clinical response. The substantial differences and often conflicting treatment approaches to IBD versus IBD-mimics directly impact the quality and cost of patient care.